Ibuprofen and acute kidney injury in the newborn

Turkish Journal of Pediatrics

Volumn 52, Issue 3, 2010, Pages 231-238

  Fanos, Vassilios ^a   Antonucci, Roberto ^a   Zaffanello, Marco ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Ibuprofen; Indomethacin; Kidney injury; Newborn; Patent ductus arteriosus

Indexed keywords

ACETYLSALICYLIC ACID; AMIKACIN; GENTAMICIN; IBUPROFEN; IBUPROFEN LYSINE; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; VANCOMYCIN; BIOLOGICAL MARKER; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR;

ACUTE KIDNEY FAILURE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FLUID RETENTION; HEMATURIA; HUMAN; IC 50; KIDNEY DISEASE; KIDNEY INJURY; NONHUMAN; OLIGURIA; PATENT DUCTUS ARTERIOSUS; PREMATURITY; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; ANIMAL; KIDNEY; NEWBORN; URINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DUCTUS ARTERIOSUS, PATENT; HUMANS; IBUPROFEN; INDOMETHACIN; INFANT, NEWBORN; INFANT, PREMATURE; KIDNEY;

EID: 77956798590     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Sekar KC, Corff KE. Treatment of patent ductus arteriosus: indomethacin or ibuprofen? J Perinatol 2008; 28: S60-62.
2. Katzung BG. Basic and Clinical Pharmacology (8th ed). New York: Mc Graw-Hill; 2001.
3. Van Overmeire B, Chemtob S. The pharmacologic closure of the patent ductus arteriosus. Semin Fetal Neonatal Med 2005; 10: 177-184.
4. NeoProfen (ibuprofen lysine) injection (package insert). Deerfield, IL: Ovation Pharmaceuticals; 2006.
5. Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2008; 23: CD003481.
6. Pezzati M, Vangi V, Biagiotti R, Bertini G, Cianciulli D, Rubaltelli FF. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr 1999; 135: 733-738.
7. Van Overmeire B, Smets K, Lecoutere D, et al. A comparison of ibuprofen and indomethacin. N Engl J Med 2000; 343: 674-681.
8. Lago P, Bettiol T, Salvadori S, et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. Eur J Pediatr 2002; 161: 202-207.
9. Chotigeat U, Jirapapa K, Layangkool T. A comparison of oral ibuprofen and intravenous indomethacin for closure of patent ductus arteriosus in preterm infants. J Med Assoc Thai 2003; 86: S563-569.
10. Su PH, Chen JY, Su CM, Huang TC, Lee HS. Comparison of ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants. Pediatr Int 2003; 45: 665-670.
11. Gimeno Navarro A, Cano Sánchez A, Fernández Gilino C, et al. [Ibuprofen versus indomethacin in the treatment of patent ductus arteriosus in preterm infants]. An Pediatr (Barc) 2005; 63: 212-218.
12. Su BH, Lin HC, Chiu HY, Hsieh HY, Chen HH, Tsai YC. Comparison of ibuprofen and indomethacin for early-targeted treatment of patent ductus arteriosus in extremely premature infants: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 2008; 93: F94-99.
13. Thomas RL, Parker GC, Van Overmeire B, Aranda JV. A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. Eur J Pediatr 2005; 164: 135-140.
14. Aranda JV, Thomas R. Systematic review: intravenous ibuprofen in preterm newborns. Semin Perinatol 2006; 30: 114-120.
15. Cataldi L, Leone R, Moretti U, et al. Potential risk factors for the development of acute renal failure in preterm newborn infants: a case-control study. Arch Dis Child Fetal Neonatal Ed 2005; 90: F514-519.
16. Benini D, Fanos V, Cuzzolin L, Tato L. In utero exposure to nonsteroidal anti-inflammatory drugs: neonatal renal failure. Pediatr Nephrol 2004; 19: 232-234.
17. Fanos V, Cataldi L. Renal transport of antibiotics and nephrotoxicity: a review. J Chemother 2001; 13: 461-472.
18. Chen N, Aleksa K, Woodland C, Rieder M, Koren G. Ontogeny of drug elimination by the human kidney. Pediatr Nephrol 2006; 21: 160-168.
19. Buist SC, Cherrington NJ, Choudhuri S, Hartley DP, Klaassen CD. Gender-specific and developmental influences on the expression of rat organic anion transporters. J Pharmacol Exp Ther 2002; 301: 145-151.
20. Cuzzolin L, Dal Cere M, Fanos V. NSAID-induced nephrotoxicity from the fetus to the child. Drug Saf 2001; 24: 9-18.
21. Langhendries JP, van Overmeire B. Prostaglandines, anti-inflammatoires non stéroïdiens (AINS) et rein périnatal: un subtil compromis. In: Guignard JP (ed). Néphrologie Périnatale. Vol. 4. Paris: Elsevier; 2001: 36-58.
22. Antonucci R, Cuzzolin L, Arceri A, Fanos V. Urinary prostaglandin E2 in the newborn and infant. Prostaglandins Other Lipid Mediat 2007; 84: 1-13.
23. Agostiniani R, Mariotti P, Cataldi L, et al. Role of renal PGE2 in the adaptation from foetal to extrauterine life in term and preterm infants. Prostaglandins Leukot Essent Fatty Acids 2002; 67: 373-377.
24. Fanos V, Cuzzolin L. Causes and manifestation of nephrotoxicity. In: Shaefer F, Geary F (eds). Clinical Pediatric Nephrology. Philadelphia: Mosby Elsevier; 2008.
25. Desfrere L, Zohar S, Morville P, et al. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. J Clin Pharm Ther 2005; 30: 121-132.
26. Hirt D, Van Overmeire B, Treluyer JM, et al. An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. Br J Clin Pharmacol 2008; 65: 629-636.
27. Gregoire N, Desfrere L, Roze JC, Kibleur Y, Koehne PJ. Population pharmacokinetic analysis of ibuprofen enantiomers in preterm newborn infants. Clin Pharmacol 2008; 48: 1460-1468.
28. Ma JD, Nafziger AN, Bertino JS Jr. Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers. J Clin Pharmacol 2004; 44: 447-456.
29. Fanos V, Cataldi L. Antibacterial-induced nephrotoxicity in the newborn. Drug Saf 1999; 20: 245-267.
30. Allegaert K, Cossey V, Langhendries JP, et al. Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life. Biol Neonate 2004; 86: 207-211.
31. Allegaert K, Vanhole C, de Hoon J, et al. Nonselective cyclo-oxygenase inhibitors and glomerular filtration rate in preterm neonates. Pediatr Nephrol 2005; 20: 1557-1561.
32. Allegaert K, Rayan M, Anderson BJ. Impact of ibuprofen administration on renal drug clearance in the first weeks of life. Methods Find Exp Clin Pharmacol 2006; 28: 519-522.
33. Allegaert K, Cossey V, Debeer A, et al. The impact of ibuprofen on renal clearance in preterm infants is independent of the gestational age. Pediatr Nephrol 2005; 20: 740-743.
34. Fanos V, Benini D, Verlato G, Errico G, Cuzzolin L. Efficacy and renal tolerability of ibuprofen vs. indomethacin in preterm infants with patent ductus arteriosus. Fundam Clin Pharmacol 2005; 19: 187- 193.
35. Gimeno Navarro A, Modesto Alapont V, Morcillo Sopena F, et al. [Ibuprofen versus indomethacin in the preterm persistent patent ductus arteriosus therapy: review and meta-analysis]. An Pediatr (Barc) 2007; 67: 309-318.
36. Giniger RP, Buffat C, Millet V, Simeoni U. Renal effects of ibuprofen for the treatment of patent ductus arteriosus in premature infants. J Matern Fetal Neonatal Med 2007; 20: 275-283.
37. Hammerman C, Shchors I, Jacobson S, et al. Ibuprofen versus continuous indomethacin in premature neonates with patent ductus arteriosus: is the difference in the mode of administration? Pediatr Res 2008; 64: 291-297.
38. Cherif A, Khrouf N, Jabnoun S, et al. Randomized pilot study comparing oral ibuprofen with intravenous ibuprofen in very low birth weight infants with patent ductus arteriosus. Pediatrics 2008; 122: e1256-1261.
39. Keady S, Grosso A. Ibuprofen in the management of neonatal patent ductus arteriosus. Intensive Crit Care Nurs 2005; 21: 56-58.
40. Mounier G, Guy C, Berthoux F, Beyens MN, Ratrema M, Ollagnier M. [Severe renal adverse events with arylcarboxylic non-steroidal anti-inflammatory drugs: results of a eight-year French national survey]. Therapie 2006; 61: 255-266.
41. Flávia CD, Georgetti FC, de Rezende Eugênio G. Treatment of patent ductus arteriosus in preterm infants with enteral ibuprofen. Rev Paul Pediatria 2006; 24: 135-142.
42. Tiker F, Yildirim SV. Acute renal impairment after oral ibuprofen for medical closure of patent ductus arteriosus. Indian Pediatr 2007; 44: 54-55.
43. Erdeve O, Sarici SU, Sari E, Gok F. Oral-ibuprofeninduced acute renal failure in a preterm infant. Pediatr Nephrol 2008; 23: 1565-1567.
44. Cuzzolin L, Fanos V, Pinna B, et al. Postnatal renal function in preterm newborns: a role of diseases, drugs and therapeutic interventions. Pediatr Nephrol 2006; 21: 931-938.
45. Cataldi L, Mussap M, Bertelli L, Ruzzante N, Fanos V, Plebani M. Cystatin C in healthy women at term pregnancy and in their infant newborns: relationship between maternal and neonatal serum levels and reference values. Am J Perinatol 1999; 16: 287-295.
46. Zaffanello M, Franchini M, Fanos V. Is serum cystatin-C a suitable marker of renal function in children? Ann Clin Lab Sci 2007; 37: 233-240.
47. Armangil D, Yurdakök M, Canpolat FE, Korkmaz A, Yiǧit S, Tekinalp G. Determination of reference values for plasma cystatin C and comparison with creatinine in premature infants. Pediatr Nephrol 2008; 23: 2081-2083.
48. Zanardo V, Vedovato S, Lago P, Piva D, Faggian D, Chiozza L. Effects of ibuprofen and indomethacin on urinary antidiuretic hormone excretion in preterm infants treated for patent ductus arteriosus. Fetal Diagn Ther 2005; 20: 534-539.
49. Zanardo V, Vedovato S, Lago P, et al. Urinary ET- 1, AVP and sodium in premature infants treated with indomethacin and ibuprofen for patent ductus arteriosus. Pediatr Nephrol 2005; 20: 1552-1556.
50. Zanardo V, Vedovato S, Chiozza L, Faggian D, Favaro F, Trevisanuto D. Pharmacological closure of patent ductus arteriosus: effects on pulse pressure and on endothelin-1 and vasopressin excretion. Am J Perinatol 2008; 25: 353-358.
51. Guignard JP, Gouyon JB. Glomerular filtration rate in neonate. In: Oh WK, Guignard JP, Baumgart S (eds). Nephrology and Fluid Electrolyte Physiology. Philadelphia: Elsevier Saunders; 2008.
52. Kent AL, Maxwell LE, Koina ME, Falk MC, Willenborg D, Dahlstrom JE. Renal glomeruli and tubular injury following indomethacin, ibuprofen, and gentamicin exposure in a neonatal rat model. Pediatr Res 2007; 62: 307-312.
53. Guignard JP. The adverse renal effects of prostaglandinsynthesis inhibitors in the newborn rabbit. Semin Perinatol 2002; 26: 398-405.
54. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vanen JR. Selectivity of non steroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994; 90: 11693-11697.
55. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenaseindependent actions of cyclooxygenase inhibitors. FASEB J 2001; 15: 2057-2072.
56. Hasan J, Beharry KD, Gharraee Z, et al. Early postnatal ibuprofen and indomethacin effects in suckling and weanling rat kidneys. Prostaglandins Other Lipid Mediat 2008; 85: 81-88.
57. Devarajan P. Emerging biomarkers of acute kidney injury. Contrib Nephrol 2007; 156: 203-212.
58. Devarajan P. Proteomics for biomarker discovery in acute kidney injury. Semin Nephrol 2007; 27: 637- 651.
59. Bonventre JV. Diagnosis of acute kidney injury: from classic parameters to new biomarkers. Contrib Nephrol 2007; 156: 213-219.
60. Nickolas TL, Barasch J, Devarajan P. Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens 2008; 17: 127-132.
61. Nguyen MT, Devarajan P. Biomarkers for the early detection of acute kidney injury. Pediatr Nephrol 2008; 23: 2151-2157.
62. Antonucci R, Cuzzolin L, Arceri A, Dessì A, Fanos V. Changes in urinary PGE2 after ibuprofen treatment in preterm infants with patent ductus arteriosus. Eur J Clin Pharmacol 2009; 65: 223-230.
63. Ojala R, Ala-Houhala M, Ahonen S, et al. Renal follow up of premature infants with and without perinatal indomethacin exposure. Arch Dis Child Fetal Neonatal Ed 2001; 84: F28-33.
64. Hammerman C, Shchors I, Jacobson S, et al. Ibuprofen versus continuous indomethacin in premature neonates with patent ductus arteriosus: is the difference in the mode of administration? Pediatr Res 2008; 64: 291-297.